J Clin Neurol.  2020 Jan;16(1):160-162. 10.3988/jcn.2020.16.1.160.

Refractory Digital Ulcers Treated by Botulinum Toxin and Endothelin Receptor-1 Antagonist in Anti-MDA5-Antibody-Positive Dermatomyositis

• Min HK
• Kim HR
• Lee SH
• Park SH
• Oh J
• Choi K

• KMID: 2467801
• DOI: http://doi.org/10.3988/jcn.2020.16.1.160

Abstract

No abstract available.

MeSH Terms

Botulinum Toxins*
Dermatomyositis*
Endothelins*
Ulcer*
Botulinum Toxins
Endothelins

Figure

• 

  Fig. 1 Muscle biopsy and dermatologic manifestations of the anti-MDA5-Ab-positive dermatomyositis patient. A: Hematoxylin and eosin staining of the vastus lateralis muscle showed minimal size variations of myofibers and revealed some atrophic myofibers (arrows) in the perifascicular area. There was no inflammatory cell infiltration in the endomysium or blood vessels (scale bar: 200 µm). B: Ultrastructurally, tubuloreticular cytoplasmic inclusions were found in endothelial cells (uranyl acetate and lead citrate stain, scale bar: 500 nm). C: Baseline multiple digital ulcers on the right second finger. D: Applying oral bosentan and botulinum toxin injection resulted in the digital ulcers improving at 12 weeks after the first injection of botulinum toxin.

Reference

1. Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018; 17:816–828.

2. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011; 65:25–34.

3. Greenberg SA. Dermatomyositis and type 1 interferons. Curr Rheumatol Rep. 2010; 12:198–203.

4. Abe Y, Matsushita M, Tada K, Yamaji K, Takasaki Y, Tamura N. Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis. Rheumatology (Oxford). 2017; 56:1492–1497.

5. Hughes M, Herrick AL. Digital ulcers in systemic sclerosis. Rheumatology (Oxford). 2017; 56:14–25.

6. Motegi S, Yamada K, Toki S, Uchiyama A, Kubota Y, Nakamura T, et al. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. J Dermatol. 2016; 43:56–62.